

RECEIVED

NOV 13 2002

ASHMET.002A1

TECH CENTER 1600/2900

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : John G. Babish et al.

Appl. No. : 09/919,349

Filed : July 31, 2001

For : COMBINATIONS OF  
SESQUITERPENE  
LACTONES AND DITERPENE  
TRIEPOXIDE LACTONES  
FOR SYNERGISTIC  
INHIBITION OF  
CYCLOOXYGENASE-2


Examiner : Michele C. Flood

) Group Art Unit 1651

) I hereby certify that this correspondence and all  
) marked attachments are being deposited with the  
) United States Postal Service as first-class mail in  
) an envelope addressed to: Assistant  
) Commissioner for Patents, Washington, D.C.  
) 20231, on

) November 4, 2002

) (Date)

) 

) Connie C. Tong, Reg. No. 52,292

RESPONSE TO RESTRICTION REQUIREMENTAssistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This communication is in response to the Office Action mailed September 18, 2002. The Examiner has required restriction to one of 5 inventions:

Group I (Claims 1-25), drawn to a composition for inhibition of inducible COX-2 activity and having minimal effect on COX-1 activity, said composition comprising as a first component an effective amount of diterpene triepoxide lactone species, and as a second component an effective amount of a sesquiterpene lactone species or derivatives thereof, classified in Class 514, subclass 175, for example;

Group II (Claims 26-30 and 32-34), drawn to a method of dietary supplementation in animals comprising administering to an animal suffering symptoms of inflammation the composition comprising , as a first component an effective amount of diterpene triepoxide lactone

**Appl. No.** : 09/919,349  
**Filed** : July 31, 2001

species and an effective amount of second component of a sesquiterpene lactone species or derivatives thereof, and continuing said administering of the composition until said symptoms are reduced, classified in Class 514, subclass 914 or Class 424, subclass 439, for example.

Group III (Claim 31), drawn to a method of therapeutic treatment in animals comprising administering to an animal suffering from symptoms of arthritis a composition comprising, as a first component an effective amount of a diterpene triepoxide lactone species and an effective amount of second component of a sesquiterpene lactone species or derivatives thereof, and continuing said administering of the composition until said symptoms are reduced, classified in Class 514, subclass 825, for example.

Group IV (Claims 35-39), drawn to a method of therapeutic treatment comprising applying to the skin of a human suffering from symptoms of acne rosacea a lotion comprising a composition comprising as a first component an effective amount of pharmaceutical grade compound selected from a recited Markush group, and as a second component an effective amount of a compound selected from a recited Markush group, classified in Class 514, subclass 859, for example.

Group V (Claims 40-42), drawn to a method of therapeutic treatment comprising applying to the skin of a human suffering symptoms of psoriasis a lotion comprising a composition comprising as a first component an effective amount of pharmaceutical grade triptolide, and as a second component an effective amount of a compound selected from a recited Markush group, classified in Class 514, subclass 863, for example.


**Appl. No.** : 09/919,349  
**Filed** : July 31, 2001

Applicant hereby elects, without traverse, to prosecute the claims directed to Group I, classified in Class 514, Subclass 175, in the present application. Applicant reserves the right to pursue the remaining claims in a divisional application. Accordingly, prompt examination on the merits of Claims 1-25 is respectfully requested.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: November 4, 2002

By:   
Connie C. Tong  
Registration No. 52,292  
Agent of Record  
2040 Main Street  
Fourteenth Floor  
Irvine, CA 92614  
(949) 760-0404

H:\DOCS\CC\T\CC-T-3324.DOC  
110202